Drugs /

levonorgestrel-releasing intrauterine system

Back to Drugs List

Overview

NCI Definition [1]:
A long-acting, hormone-releasing, intrauterine device consisting of a small, T-shaped, polyethylene frame and a reservoired synthetic progesterone with progestational and potential antineoplastic activities. After insertion of this system into the uterus, the device slowly and gradually releases the hormone. Levonorgestrel acts by binding to the progesterone receptor in the nuclei of target cells, resulting in transcription activation and an alteration in protein synthesis. Subsequently, luteinizing hormone (LH) activity and ovulation are suppressed. Levonorgestrel may also exhibit antiproliferative activity in endometrial tissue.

Clinical Trials

View Clinical Trials for levonorgestrel-releasing intrauterine system

Levonorgestrel-releasing intrauterine system has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating levonorgestrel-releasing intrauterine system, 1 is phase 2 (1 open).

Endometrial endometrioid adenocarcinoma is the most common disease being investigated in levonorgestrel-releasing intrauterine system clinical trials [2].

Drug Details

Synonyms [2]:
levonorgestrel-releasing intrauterine system, levonorgestrel berlex brand, lng-ius, berlex brand of levonorgestrel, levonorgestrel-releasing intrauterine system, mirena, schering brand 1 of levonorgestrel, levonorgestrel-releasing intrauterine system (product)
NCIT ID [1]:
C52193
SNOMED ID [1]:
C-F071A

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.